Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CardioWest total artificial heart: a retrospective controlled study.

F A Arabia1, J G Copeland, R G Smith

  • 1Health Sciences Center, University of Arizona, Tucson 85724-5071, USA. arabia@u.arizona.edu

Artificial Organs
|February 23, 1999
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progress on the total artificial heart.

Surgical technology international·2015
Same author

Long term results of bivalvular mechanical replacement: A historical thirty year follow-up.

International journal of cardiology·2015
Same author

Who gets a second heart? A current picture of cardiac retransplantation.

Transplantation proceedings·2014
Same author

Bridge to transplantation using paracorporeal biventricular assist devices or the syncardia temporary total artificial heart: is there a difference?

The Journal of cardiovascular surgery·2014
Same author

[Creation of software to help cardiac surgeons: CordaBase].

Vestnik khirurgii imeni I. I. Grekova·2013
Same author

Total artificial heart in the pediatric patient with biventricular heart failure.

Perfusion·2013

The CardioWest total artificial heart (TAH) significantly improves survival rates for heart transplant candidates awaiting a donor heart. This pneumatic device offers a successful bridge to transplantation, replacing failing ventricles with a reasonable risk profile.

Area of Science:

  • Cardiology
  • Medical Devices
  • Transplantation Surgery

Background:

  • The CardioWest total artificial heart (TAH) is a pneumatic device designed to replace failing ventricles.
  • It serves as a crucial bridge to heart transplantation for critically ill patients.
  • The TAH is approved by the Food and Drug Administration (FDA) and used in select U.S. centers.

Purpose of the Study:

  • To evaluate the efficacy and survival rates of the CardioWest TAH as a bridge to heart transplantation.
  • To compare outcomes of patients bridged with the TAH versus those on the waiting list.

Main Methods:

  • A retrospective study comparing two groups of heart transplant candidates (Group A: received TAH, Group B: control).
  • Patients in Group A (n=24) received the CardioWest TAH between January 1993 and July 1996.

Related Experiment Videos

  • Group B (n=18) met TAH criteria but did not receive the device; preimplantation data including pulmonary vascular resistance, creatinine, and bilirubin were analyzed.

    • Main Results:

    • The TAH group (Group A) achieved a 91.7% survival rate, with 22 of 24 patients transplanted and discharged.
    • The control group (Group B) had a survival rate of 38.9%, with 7 of 18 transplanted patients surviving.
    • A statistically significant difference (p = 0.0003) in survival was observed between the groups.

    Conclusions:

    • The CardioWest TAH is an effective and successful method for bridging patients to heart transplantation.
    • It offers a viable option for patients with end-stage ventricular failure awaiting transplant.
    • The study demonstrates a significant survival benefit for patients receiving the TAH compared to the control group.